Advertisement
Research ArticleDrug Discovery and Translational Medicine

Neutral Endopeptidase-Resistant C-Type Natriuretic Peptide Variant Represents a New Therapeutic Approach for Treatment of Fibroblast Growth Factor Receptor 3–Related Dwarfism

Daniel J. Wendt, Melita Dvorak-Ewell, Sherry Bullens, Florence Lorget, Sean M. Bell, Jeff Peng, Sianna Castillo, Mika Aoyagi-Scharber, Charles A. O’Neill, Pavel Krejci, William R. Wilcox, David L. Rimoin and Stuart Bunting
Journal of Pharmacology and Experimental Therapeutics April 2015, 353 (1) 132-149; DOI: https://doi.org/10.1124/jpet.114.218560
Submit a Response to This Article
Compose eLetter

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

Vertical Tabs

Jump to comment:

No eLetters have been published for this article.
Back to top

In this issue

Download PDF
Article Alerts
Email Article
Citation Tools

Research ArticleDrug Discovery and Translational Medicine

C-Type Natriuretic Peptide Variant for FGFR3-Related Dwarfism

Daniel J. Wendt, Melita Dvorak-Ewell, Sherry Bullens, Florence Lorget, Sean M. Bell, Jeff Peng, Sianna Castillo, Mika Aoyagi-Scharber, Charles A. O’Neill, Pavel Krejci, William R. Wilcox, David L. Rimoin and Stuart Bunting
Journal of Pharmacology and Experimental Therapeutics April 1, 2015, 353 (1) 132-149; DOI: https://doi.org/10.1124/jpet.114.218560
Twitter logo Facebook logo Mendeley logo

Jump to section

Advertisement